

FORM PTO-1449

ATTY. DOCKET NO.
39187-1457SERIAL NO.
09/942,959LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
OSBAKKEN *et al.*FILING DATE
August 31, 2001GROUP
1616

* If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120, 37 C.F.R. § 1.98(d).

+ Derwent English language abstract and/or English translation provided.

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
<i>JD</i>	A	0	0	5	2	3	3	8	05/02/02	Yerxa <i>et al.</i>	514	47	12/03/01
	B	0	0	6	5	2	4	4	05/30/02	Yerxa <i>et al.</i>	514	47	11/09/01
	C	0	1	0	3	1	5	7	08/01/02	Yerxa <i>et al.</i>	514	47	01/03/02
	D	4	3	1	2	8	6	0	01/26/82	Clements	424	199	10/24/80
	E	4	3	5	5	0	2	1	10/19/82	Mahl <i>et al.</i>	424	28	10/29/80
	F	4	4	2	4	2	1	6	01/03/84	Cerami <i>et al.</i>	424	211	07/31/79
	G	4	4	6	8	5	1	3	08/28/84	Kirst <i>et al.</i>	536	16.8	09/07/82
	H	4	4	7	8	8	2	2	10/23/84	Haslam <i>et al.</i>	424	78	05/16/83
	I	4	4	8	6	4	1	8	12/04/84	Watanabe <i>et al.</i>	424	180	06/06/83
	J	4	4	9	3	8	3	1	01/15/85	Takaya <i>et al.</i>	424	180	09/30/83
	K	4	5	5	4	2	6	9	11/19/85	Takaya <i>et al.</i>	514	35	01/24/84
	L	4	5	7	1	3	3	4	02/18/86	Yoshida <i>et al.</i>	424	95	12/04/91
	M	4	5	9	3	0	8	9	06/03/86	Wang <i>et al.</i>	536	13.6	10/31/83
	N	4	6	1	7	2	9	3	10/14/86	Wahlig <i>et al.</i>	514	41	05/23/84
	O	4	6	4	7	6	5	6	03/03/87	Watanabe <i>et al.</i>	536	16.1	08/14/84
	P	4	6	5	6	1	6	0	04/07/87	Takaya <i>et al.</i>	514	41	11/18/85
	Q	4	6	8	4	6	4	3	08/04/87	Buddenbaum <i>et al.</i>	514	204	06/03/85
	R	4	7	4	9	7	0	0	06/07/88	Wenig	514	225.2	04/24/87
	S	4	8	5	5	2	8	7	08/08/89	Watanabe <i>et al.</i>	514	41	09/03/86
<i>JD</i>	T	4	9	0	6	4	7	6	03/06/90	Radhakrishnan	424	450	12/14/88
	U	5	0	0	4	6	1	1	04/02/91	Keigh	424	450	03/21/88

EXAMINER

DATE CONSIDERED

11/7/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **AEROSOLIZED ANTI-INFECTIVES, ANTI-INFLAMMATORIES, AND DECONGESTANTS FOR THE TREATMENT OF SINUSITIS**

FORM PTO-1449

SEP 11 2003

ATTY. DOCKET NO.
39187-1457SERIAL NO.
09/942,959LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
OSBAKKEN *et al.*FILING DATE
August 31, 2001GROUP
1616

* If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

+ Derwent English language abstract and/or English translation provided.

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
<i>[initials]</i>	V	5	0	0	6	3	4	3	04/09/91	Benson <i>et al.</i>	424	450	12/29/88
	W	5	0	3	9	6	6	6	08/13/91	Novick, Jr.	517	37	10/30/90
	X	5	0	4	9	3	8	8	09/17/91	Knight <i>et al.</i>	424	450	07/21/89
	Y	5	0	4	9	3	8	9	09/17/91	Radhakrishnan	424	450	12/01/89
	Z	5	1	1	0	8	0	6	05/05/92	Clements	514	78	04/07/89
	AA	5	1	1	2	8	0	4	05/12/92	Kowarski	514	3	09/14/89
	AB	5	1	4	1	6	7	4	08/25/92	Keigh	252	305	06/24/91
	AC	5	1	6	7	5	0	6	12/01/92	Kilis <i>et al.</i>	434	262	10/24/91
	AD	5	1	6	9	6	3	7	12/08/92	Kenk <i>et al.</i>	424	450	04/02/91
	AE	5	2	9	9	5	6	6	04/05/94	Davis <i>et al.</i>	128	200	09/18/92
	AF	5	5	0	8	2	6	9	04/16/96	Smith <i>et al.</i>	514	38	10/19/94
	AG	5	5	1	2	2	6	9	04/30/96	Molina y Vedia <i>et al.</i>	424	45	06/09/93
	AH	5	5	2	2	3	8	5	06/04/96	Lloyd <i>et al.</i>	128	203.26	09/27/94
	AI	5	5	2	5	3	2	9	06/11/96	Snyder <i>et al.</i>	424	45	01/03/95
	AJ	5	5	6	7	7	1	6	10/22/96	Della Valle <i>et al.</i>	514	332	11/19/93
	AK	5	5	9	5	9	7	7	01/21/97	Dyrsting <i>et al.</i>	514	39	10/27/93
	AL	5	6	1	4	2	1	6	03/25/97	Janoff	424	450	05/16/95
	AM	5	6	2	4	9	6	2	01/21/97	Dyrsting <i>et al.</i>	514	39	10/27/93
	AN	5	6	5	5	5	2	3	08/12/97	Hodson <i>et al.</i>	128	315	05/22/95
	AO	5	6	8	5	2	9	1	11/11/97	Marsh	128	200.15	11/15/96
<i>[initials]</i>	AP	5	8	6	1	2	7	5	01/19/99	Hansen	435	69.1	09/28/95

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **AEROSOLIZED ANTI-INFECTIVES, ANTI-INFLAMMATORIES, AND DECONGESTANTS FOR THE TREATMENT OF SINUSITIS**

FORM PTO-1449


SEP 11 2003

ATTY. DOCKET NO.
39187-1457SERIAL NO.
09/942,959LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
OSBAKKEN *et al.*FILING DATE
August 31, 2001GROUP
1616


* If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120, 37 C.F.R. § 1.98(d).

+ Derwent English language abstract and/or English translation provided.

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	AQ	5	8	9	7	8	7	2	04/27/99	Picciano	424	434	11/12/97
	AR	5	9	0	0	4	0	6	05/04/99	von Ahsen <i>et al.</i>	514	35	06/08/94
	AS	5	9	0	0	4	0	7	05/04/99	Yerxa <i>et al.</i>	514	47	02/06/97
	AT	5	9	0	6	1	9	8	05/25/99	Flickinger	128	200.21	07/14/97
	AU	5	9	8	5	2	5	9	11/16/99	Cagle <i>et al.</i>	424	78.04	04/30/97
	AV	6	0	3	7	3	5	8	03/14/00	Gordziel	514	357	03/24/99
	AW	6	0	8	3	9	2	2	07/04/00	Montgomery	514	38	04/02/97
	AX	6	2	4	1	9	6	9	06/05/01	Saidi <i>et al.</i>	424	45	06/26/98
	AY	6	2	7	7	8	5	5	08/21/01	Yerxa	514	256	04/21/00
	AZ	6	3	3	1	5	2	9	12/18/01	Yerxa <i>et al.</i>	514	47	02/25/00
	BA	6	3	8	7	8	8	6	B1 05/14/02	Montgomery <i>et al.</i>	514	34	11/28/01
	BB	6	4	2	0	3	4	7	07/16/02	Jacobus <i>et al.</i>	514	51	07/17/98
	BC	6	4	2	3	6	9	4	07/23/02	Drutz <i>et al.</i>	514	51	02/21/96
	BD	6	4	3	6	9	1	0	08/20/02	Yerxa <i>et al.</i>	514	47	12/03/01
	BE	6	4	4	8	2	7	6	09/10/02	Yerxa	514	357	05/17/00
	BF	6	4	6	2	1	8	3	10/08/02	Toth <i>et al.</i>	536	17.2	08/26/99

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No	
	BG	1	0	1	3	0	1	48	05/19/98	JP (A)			X	
	BH	0	4	7	0	1	5	4	06/05/96	EP (B1)				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **AEROSOLIZED ANTI-INFECTIVES, ANTI-INFLAMMATORIES, AND DECONGESTANTS FOR THE TREATMENT OF SINUSITIS**

FORM PTO-1449

ATTY. DOCKET NO.
39187-1457SERIAL NO.
09/942,959LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
OSBAKKEN *et al.*FILING DATE
August 31, 2001GROUP
1616

* If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120, 37 C.F.R. § 1.98(d).

+ Derwent English language abstract and/or English translation provided.

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	*Ref. Code	DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation	
													Yes	No
JD	BI	0	5	0	7	7	0	7	07/12/95	EP (B1)				+X
	BJ	0	5	6	3	1	3	1	09/11/96	EP (B1)				
	BK	0	6	8	2	5	1	4	09/12/01	EP (B1)				
	BL	0	7	0	5	6	1	4	09/25/02	EP (B1)				
	BM	0	9	2	5	3	0	8	06/02/02	EP (B1)				
	BN	0	0	0	0	1	8	1	01/06/00	PCT (A1)				
	BO	0	0	5	0	0	2	4	08/31/00	PCT (A2, A3)				
	BP	0	1	0	2	0	2	4	01/11/01	PCT (A1)				
	BQ	0	1	1	9	3	4	4	03/22/01	PCT (A1)				+X
	BR	0	1	8	0	8	4	4	11/01/01	PCT (A2, A3)				
	BS	0	2	0	6	8	0	31	09/06/02	PCT (A2)				
	BT	9	7	2	9	7	5	6	08/21/97	PCT (A1)				
	BU	9	7	3	5	5	9	1	10/02/97	PCT (A2, A3)				
	BV	9	8	3	4	5	9	3	08/13/98	PCT (A1)				

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

JD	BW	Adelroth <i>et al.</i> , "Airway responsiveness to leukotrienes C ₄ and D ₄ and to methacholine in patients with asthma and normal controls", <i>N Engl J Med</i> , <u>315</u> :480-484 (1986)
	BX	Alexandrakis <i>et al.</i> , "Nasolacrimal Duct Obstruction and Orbital Cellulitis Associated With Chronic Intranasal Cocaine Abuse," <i>Arch Ophthalmol</i> , <u>117</u> :1617-1622 (1999)
	BY	Baraniuk <i>et al.</i> , "Addition of intranasal glucocorticoids to standard antibiotic therapy for sinusitis", <i>Current Allergy and Asthma Rep</i> , <u>1</u> (3):191-192 (2001)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **AEROSOLIZED ANTI-INFECTIVES, ANTI-INFLAMMATORIES, AND DECONGESTANTS FOR THE TREATMENT OF SINUSITIS**

FORM PTO-1449

ATTY. DOCKET NO.
39187-1457SERIAL NO.
09/942,959LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
OSBAKKEN *et al.*FILING DATE
August 31, 2001GROUP
1616

* If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120, 37 C.F.R. § 1.98(d).

+ Derwent English language abstract and/or English translation provided.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

BZ	Bell <i>et al.</i> , "A-78773: a selective, potent 5-lipoxygenase inhibitor", <i>J Lipid Mediators</i> , <u>6</u> :259-264 (1993)
CA	Bhattacharyya <i>et al.</i> , "The Microbiology of Recurrent Rhinosinusitis After Endoscopic Sinus Surgery", <i>Arch Otolaryngol Head Neck Surg</i> , <u>125</u> (10):1117-1120 (1999)
CB	Boner <i>et al.</i> , "A combination of cefuroxime and N-acetyl-cysteine for the treatment of maxillary sinusitis in children with respiratory allergy", <i>Int J Clin Pharmacol Ther Toxicol</i> , <u>22</u> (9):511-514 (1984)
CC	Boyce <i>et al.</i> , "MRSA patients: proven methods to treat colonization and infection," <i>Journal of Hospital Infection</i> , <u>48</u> (Supplement A):S9-S14 (2001)
CD	Braun <i>et al.</i> , "Adjunct effect of loratadine in the treatment of acute sinusitis in patients with allergic rhinitis", <i>Allergy</i> , <u>52</u> (6):650 (1997)
CE	Certified English Translation for Japanese Patent Application (Kokai) No. 10-130148 entitled: "Composition for Nebulizers".
CF	Cimochowski <i>et al.</i> , "Intranasal Mupirocin Reduces Sternal Wound Infection After open Heart Surgery in Diabetics and Nondiabetics," <i>Ann Thorac Surg</i> , <u>71</u> :1572-1579 (2001)
CG	Cohen, M.L., "Antimicrobial resistance: prognosis for public health", <i>Trends Microbiol</i> , <u>2</u> :422-425 (1994)
CH	Dahlen <i>et al.</i> , "Leukotrienes are potent constrictors of human bronchi", <i>Nature</i> , <u>288</u> :484-486 (1980)
CI	Derwent# 009206491, W.P.I. Acc No: 1992-333912/199241, for European Patent Application, EP 507707 A, "Control unit for therapeutic nebuliser - has sonic vibration control chamber made separate from over-pressure control chamber and linked to pulsed air source".
CJ	Derwent# 013773627, W.P.I. Acc No.: 2001-257838/200126, for PCT Patent Application, WO 200119344 A1, "Preparing powders for nasal atomization, useful e.g. for administering Vitamin B12, using water insoluble, absorbent excipient to carry active ingredient".

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Titl : **AEROSOLIZED ANTI-INFECTIVES, ANTI-INFLAMMATORIES, AND DECONGESTANTS FOR THE TREATMENT OF SINUSITIS**

FORM PTO-1449

SEP 11 2003

ATTY. DOCKET NO.
39187-1457SERIAL NO.
09/942,959LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
OSBAKKEN *et al.*FILING DATE
August 31, 2001GROUP
1616

* If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120, 37 C.F.R. § 1.98(d).

+ Derwent English language abstract and/or English translation provided.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CK	Desrosiers <i>et al.</i> , "Treatment of chronic rhinosinusitus refractory to other treatments with topical antibiotic therapy delivered by means of a large-particle nebulizer: Results of a controlled trial," <i>Arch Otolaryngol Head Neck Surg</i> , <u>125</u> :265-269 (2001)
CL	Dolor <i>et al.</i> , "Comparison of Cefuroxime With or Without Intranasal Fluticasone for the Treatment of Rhinosinusitis," <i>J Am Med Assoc</i> , <u>286</u> :3097-3105 (2001)
CM	Dunbar, C.A. and A.J. Hickey, "Evaluation of Probability Density Functions To Approximate Particle Size Distributions of Representative Pharmaceutical Aerosols," <i>J Aerosol Sci</i> , <u>31</u> (7):813-831 (2000)
CN	Etkins <i>et al.</i> , "Sinusitis", <i>Nidus Information Services, Inc. Well-Connected Report #62: Sinusitis</i> , www.well-connected.com (2002)
CO	Farr, B.M., "Mupirocin to Prevent <i>S. Aureus</i> Infections," <i>N.E. J Med</i> , <u>346</u> (24):1905-1906 (2002)
CP	Gürses <i>et al.</i> , "Cefuroxime axetil in the treatment of acute sinusitis in childhood", <i>J Antimicrob Chemother</i> , <u>38</u> :547-550 (1996)
CQ	Hiramatsu <i>et al.</i> , "MRSA Infections in an Intensive Care Unit," <i>Masui</i> , <u>49</u> :867-871 (2000)
CR	Hitomi <i>et al.</i> , "Control of a methicillin-resistant <i>Staphylococcus aureus</i> outbreak in a neonatal intensive care unit by unselective use of nasal mupirocin ointment," <i>J Hosp Infect</i> , <u>46</u> :123-129 (2000)
CS	Holmström, M., "Nasal polyposis - of interest to several specialities. Improvements in diagnosis and new treatment methods," <i>Lakartidningen</i> , <u>97</u> (34):3611-3615 (2000)
CT	Jeong <i>et al.</i> , "Intranasal mupirocin for prevention of hospital MRSA infection," <i>ASHP-Mid-year Clin Mtg, Abstract of Meeting Presentation</i> , <u>33</u> (Dec):INTL-21 (1998)
CU	Kaiser <i>et al.</i> , "Impact of Zanamivir on Antibiotic Use for Respiratory Events Following Acute Influenza in Adolescents and Adults," <i>Arch Intern Med</i> , <u>160</u> :3234-3240 (2000)
CV	Knowles, S., "Five-day otitis media therapy. Cisapride monitoring in children. Efficacy of sumatriptan nasal spray. Testosterone for AIDS wasting.," <i>Pharm Prac</i> , (Canada) <u>14</u> :28-30 (1998)
CW	Koltai <i>et al.</i> , "Pseudomonas Aeruginosa In Chronic Maxillary Sinusitis", <i>Laryngoscope</i> , <u>95</u> :34-37 (1985)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **AEROSOLIZED ANTI-INFECTIVES, ANTI-INFLAMMATORIES, AND DECONGESTANTS FOR THE TREATMENT OF SINUSITIS**

FORM PTO-1449

SEP 11 2003

ATTY. DOCKET NO.
39187-1457SERIAL NO.
09/942,959LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
OSBAKKEN *et al.*FILING DATE
August 31, 2001GROUP
1616

* If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

+ Derwent English language abstract and/or English translation provided.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

CX	Lane <i>et al.</i> , "Leukotriene antagonism in asthma and rhinitis", <i>Respir Med</i> , <u>92</u> :795-809 (1998)
CY	Lim <i>et al.</i> , "In vivo evaluation of novel hyaluronan/chitosan microparticulate delivery systems for the nasal delivery of gentamicin in rabbits," <i>Intern J Pharm</i> , <u>231</u> :73-82 (2002)
CZ	Maccabee, M. and P.H. Hwang, "Medical Therapy of Acute and Chronic Frontal Rhinosinusitis," <i>Otolaryngol Clin N. Am</i> , <u>34</u> :41-47 (2001)
DA	Mahajan <i>et al.</i> , "Intranasal Administration of Fusidic Acid Cream in Leprosy," <i>Indian J Leprosy</i> , <u>72</u> (4):451-455 (2000)
DB	McMillan <i>et al.</i> , "Designing therapeutically effective 5-lipoxygenase inhibitors", <i>Trends Pharmacy Sci</i> , <u>13</u> :323-330 (1992)
DC	Meltzer <i>et al.</i> , "Added relief in the treatment of acute recurrent sinusitis with adjunctive mometasone furoate nasal spray," <i>J Allergy Clin Immunol</i> , <u>106</u> :630-637 (2000)
DD	Nagl <i>et al.</i> , "Activity of N-chlorotaurine against herpes simplex- and adenoviruse", <i>Antiviral Res</i> , <u>38</u> :25-30 (1988)
DE	Nagl <i>et al.</i> , "Bactericidal Activity of Micromolar N-Chlorotaurine: Evidence for Its Antimicrobial Function in the Human Defense System", <i>Antimicrobial Agents and Chemotherapy</i> , <u>44</u> (9):2507-2513 (2000)
DF	Nardi <i>et al.</i> , "Reduction in Gram-positive pneumonia and antibiotic consumption following the use of a SDD protocol including nasal and oral mupirocin," <i>Eur J Emergency Med</i> , <u>8</u> :203-214 (2001)
DG	Neher <i>et al.</i> , "N-Chlorotaurine, a Novel Endogenous Antimicrobial Agent", <u>127</u> :530-533 (2001)
DH	Nichol <i>et al.</i> , "Effectiveness of Live, Attenuated Intranasal Influenza Virus Vaccine in Healthy, Working Adults," <i>J Am Med Assoc</i> , <u>282</u> (2):137-144 (1999)
DI	Oszi <i>et al.</i> , "Quantitative determination of polysorbate 20 in nasal pharmaceutical preparations by high-performance liquid chromatography", <u>18</u> :715-720 (1998)
DJ	Package Insert for: <i>Proventil</i> ® (brand of albuterol sulfate), Schering Corporation, 1986

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **AEROSOLIZED ANTI-INFECTIVES, ANTI-INFLAMMATORIES, AND DECONGESTANTS FOR THE TREATMENT OF SINUSITIS**

FORM PTO-1449

SEP 11 2003

ATTY. DOCKET NO.
39187-1457SERIAL NO.
09/942,959LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
OSBAKKEN *et al.*FILING DATE
August 31, 2001GROUP
1616

* If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

+ Derwent English language abstract and/or English translation provided.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

DK	Package Insert for: <i>Pulmicort Respules™ (Budesonide inhalation suspension)</i> , AstraZeneca, 2000
DL	Package Insert for: <i>Pulmicort Turbuhaler 200 mcg (Budesonide inhalation powder)</i> , AstraZeneca, 2001
DM	Press Release, "Atlantic Technology Ventures, Inc. Licenses World Wide Rights to ATV-02 Antimicrobial Agent", <i>Atlantic Technology Ventures</i> , pgs 1-3, http://biz.yahoo.com/bw/020709/92194_1.html (2002)
DN	Perkins <i>et al.</i> , "Hemothorax in 2 Horses," <i>J Vet Intern Med</i> , 13 :375-378 (1999)
DO	Perl <i>et al.</i> , "Intranasal Mupirocin to Prevent Postoperative <i>Staphylococcus Aureus</i> Infections," <i>N.E. J Med</i> , 346 (24):1871-1877 (2002)
DP	Raikhlin-Eisenkraft, B. and Y. Bentur, " <i>Ecbalium elaterium</i> (Squirting Cucumber)- Remedy or Poison," <i>Clin Toxicol</i> , 38 (3):305-308 (2000)
DQ	Reicin <i>et al.</i> , "Montelukast, a Leukotriene Receptor Antagonist, in Combination With Loratadine, a Histamine Receptor Antagonist, in Combination With Loratadine, a Histamine Receptor Antagonist, in the Treatment of Chronic Asthma", <i>Arch Intern Med</i> , 160 :2481-2488 (2000)
DR	Reiss <i>et al.</i> , "Montelukast, a Once-Daily Leukotriene Receptor Antagonist, in the Treatment of Chronic Asthma", <i>Arch Intern Med</i> , 158 :1213-1220 (1998)
DS	Reiss <i>et al.</i> , "Montelukast (MK-0476), A CysLT ₁ Receptor Antagonist, Improves Asthma Outcomes Over a 3-month Treatment Period", <i>Am J Respir Crit Care Med</i> , 15 (5):A662 (1997)
DT	Reiss <i>et al.</i> , "MK-0476, An LTD ₄ Receptor Antagonist, Improves the Signs and Symptoms of Asthma with a Dose as Low as 10 mg, Once Daily", <i>Am J Respir Crit Care Med</i> , 151 :A378 (1995)
DU	Reiss <i>et al.</i> , "MK-0476, AN LTD ₄ Receptor Antagonist, Exhibits a Dose Related Improvement in the Once Daily Treatment of Patients with Chronic Asthma", <i>Eur Respir J</i> , 19 (suppl):289S (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **AEROSOLIZED ANTI-INFECTIVES, ANTI-INFLAMMATORIES, AND DECONGESTANTS FOR THE TREATMENT OF SINUSITIS**

FORM PTQ-1449

SEP 11 2003

ATTY. DOCKET NO.
39187-1457SERIAL NO.
09/942,959LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENTAPPLICANT
OSBAKKEN *et al.*FILING DATE
August 31, 2001GROUP
1616

* If an asterisk is placed beside the reference number, a copy is NOT provided because the reference was previously cited by or submitted to the PTO in a prior application that is identified in the statement and relied upon for an earlier filing date under 35 U.S.C. 120. 37 C.F.R. § 1.98(d).

+ Derwent English language abstract and/or English translation provided.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>b</i>	DV	Seggev <i>et al.</i> , "A Combination of Amoxicillin and Clavulanate Every 12 Hours vs Every 8 Hours for Treatment of Acute Bacterial Maxillary Sinusitis", <i>Arch Otolaryngol Head Neck Surg</i> , <u>124</u> :921-925 (1998)
	DW	Smith <i>et al.</i> , "The Effect of Inhaled Leukotriene D ₄ in Humans ¹⁻³ ", <i>Am Rev Respir Dis</i> , <u>131</u> :368-372 (1985)
	DX	Tracy <i>et al.</i> , "Intranasal beclomethasone as an adjunct to treatment of chronic middle ear effusion", <i>Annals of Allergy, Asthma Immunol</i> , <u>80</u> :198-206 (1998)
	DY	Tradename: ATV-02, "BioSpace Clinical Development: ATV-02 Detail", <i>Atlantic Technology Ventures</i> , http://www.biospace.com/ccis/detail.cfm?Clinical1ID=794920 (2002)
	DZ	Tsurita <i>et al.</i> , "Early Augmentation of Interleukin (IL)-12 Level in the Airway of Mice Administered Orally with Clarithromycin or Intranasally with IL-12 Results in Alleviation of Influenza Infection," <i>J Pharmacol Exper Therap</i> , <u>298</u> (1):362-368 (2001)
	EA	Waltimo <i>et al.</i> , "In Vitro susceptibility of <i>Candida albicans</i> to four disinfectants and their combinations", <i>Int Endod J</i> , <u>32</u> :421-429 (1999)
	EB	Wang, J. and G. Bu, "Influence of intranasal medication on the structure of the nasal mucosa", <i>Chinese Med J</i> , <u>115</u> (4):617-619 (2002)
	EC	Wang, J. and G. Bu, "Influence of the nasal mucociliary system on intranasal drug administration," <i>Chinese Med J</i> , <u>113</u> (7):647-649 (2000)
<i>ED</i>	ED	Yilmaz <i>et al.</i> , "Intranasal budesonide spray as an adjunct to oral antibiotic therapy for acute sinusitis in children," <i>Eur Arch Otorhinolaryngol</i> , <u>257</u> :256-259 (2000)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Title: **AEROSOLIZED ANTI-INFECTIVES, ANTI-INFLAMMATORIES, AND DECONGESTANTS FOR THE TREATMENT OF SINUSITIS**



Sheet 1 of 1

FORM PTO-1449 LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 39187-1457	SERIAL NO. 09/942,959	CONFIRM NO. 7962
	APPLICANT Osbakken <i>et al.</i>	CUSTOMER NO. 24961	
	FILING DATE 08/31/01	GROUP 1614	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER								DATE	NAME	CLASS	SUB CLASS	FILING DATE
	A	6	2	9	1	5	0	0		09/18/01	Ponikau	514	393	10/22/98
	B	6	5	5	5	5	6	6		04/29/03	Ponikau	514	393	05/25/01

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER								DATE	COUNTRY	Translation Yes No	

RECEIVED
OCT 27 2003
TECH CENTER 1600/2900

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)


EXAMINER

DATE CONSIDERED

10/6/03

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 39187-1457	SERIAL NO. 09/942,959	CONFIRM NO. 7962
	APPLICANT Osbakken <i>et al.</i>	CUSTOMER NO. 24961	
	FILING DATE 08/31/01	GROUP 1614	



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER								DATE	NAME	CLASS	SUB CLASS	FILING DATE
AD 13	A	4	7	6	7	6	1	2		08/10/88	Hagen et al.	424	45	01/23/87
	B	6	5	7	6	2	2	4		06/10/03	Ozbakken et al.	424	45	05/25/00

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER								DATE	COUNTRY	Translation Yes No	

(OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.))

AD	C	Drug Information Handbook, Lacy et al. Editors, Lexi-Comp, Inc, pages 23-24 and 678, (1993).
AD	D	Kohler, D. "Systemic therapy with aerosols", <i>Aerosols of Medicine. Principles, Diagnosis and Therapy</i> . Editors Moren et al., Elsevier Publishers, pages 303-319, (1993).

RECEIVED
SEP 04 2003
TECH CENTER 1600/2900

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.